Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • PSCK9

    - PMLiVE

    Amgen reports positive results from landmark cardiovascular study

    The study found significant reductions of major cardiovascular events in high-risk adults following treatment

    Genesis giveaway of a minifigure

    Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212

    Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...

    Genesis Research Group

    - PMLiVE

    Petauri™ Further Expands Global Pricing and Market Access Capabilities With Key Leadership Hires

    Rapidly growing pharmaceutical services platform announces the addition of accomplished executives to the organization’s global pricing and market access team.

    Petauri Evidence

    ISPOR partner seal

    Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program

    Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural...

    Genesis Research Group

    - PMLiVE

    Your essential guide to the World EPA Congress 2025: Top sessions and pre-reading

    The World EPA organisers have curated an exceptional programme featuring thought-provoking presentations and dynamic panel sessions led by industry leaders driving market access strategy and practice. Following the opening keynote...

    Petauri Evidence

    - PMLiVE

    AI in market access: silver bullet or spanner in the works?

    By Emily Morton-West

    Amiculum

    - PMLiVE

    What is willingness to pay? – Comparing price testing methodologies

    Heather Wellam (Senior Consultant – Market Access, Mtech Access) explores the concept of willingness to pay (WTP) and what it means for pharmaceutical and medtech pricing strategy. Read on to...

    Petauri Evidence

    Meet us at ISPOR

    Mtech Access are exhibiting at ISPOR in the US

    After many years attending ISPOR Europe, Mtech Access are excited to be attending the Global ISPOR conference May 5-8. Mtech Access are inviting ISPOR delegates to come by stand 125...

    Petauri Evidence

    regeneron headquarters

    Regeneron’s Praluent receives FDA approval for paediatric patients with genetic high cholesterol

    Patients aged eight year or older with heterozygous familial hypercholesterolaemia will be eligible to receive the treatment

    - PMLiVE

    The challenges of reimbursement and innovative pricing for cell and gene therapies

    Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...

    Avalere Health

    Early pipeline planning depicted with a pipe and data-oriented imagery.

    Why it’s time to apply a payer lens to your early pipeline planning

    Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial...

    Avalere Health

    Case study

    Using qualitative conjoint to assess willingness-to-pay

    Inizio

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links